We are live on ! Find out more
ESLAW icon

Estrella Immunopharma Warrant
ESLAW

11 hedge funds and large institutions have $212K invested in Estrella Immunopharma Warrant in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% less funds holding

Funds holding: 19 → 11 (-8)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

91% less capital invested

Capital invested by funds: $2.24M → $212K (-$2.03M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Holders
11
Holders Change
-8
Holders Change %
-42.11%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
5
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$4.73K
2
MFG
Magnus Financial Group
New York
+$2.6K

Top Sellers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
-$2.19M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$9.82K
3
CH
CVI Holdings
Delaware
-$4.78K
4
YCM
Yakira Capital Management
Connecticut
-$3.36K
5
RCM
Radcliffe Capital Management
Pennsylvania
-$2.62K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$52.1K – – –
ASM
2
ATW SPAC Management
New York
$44K -$1.97K -11,901 -6%
EFI
3
EHP Funds Inc
Canada
$41.4K – – –
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$21K – – –
SIA
5
SkyView Investment Advisors
New Jersey
$15K – – –
YCM
6
Yakira Capital Management
Connecticut
$11.2K -$3.36K -20,300 -30%
CAC
7
Cowen and Company
New York
$6.87K +$4.73K +28,597 New
CS
8
Clear Street
New York
$6.87K -$50 -300 -1%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$4.58K -$9.82K -59,317 -76%
MFG
10
Magnus Financial Group
New York
$3.77K +$2.6K +15,695 New
LCM
11
Landscape Capital Management
New Jersey
$3.4K – – –
RCM
12
Robinson Capital Management
Michigan
$1.75K -$1.95K -11,805 -50%
BFM
13
Boothbay Fund Management
New York
– -$2.19M -201,800 Closed
CH
14
CVI Holdings
Delaware
– -$4.78K -86,040 Closed
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
– -$2.05K -51,929 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$2.01K -50,920 Closed
RCM
17
Radcliffe Capital Management
Pennsylvania
– -$2.62K -50,000 Closed
WA
18
Whitebox Advisors
Minnesota
– -$2.52K -45,476 Closed
SOA
19
Sea Otter Advisors
Florida
– -$2.22K -40,000 Closed
SSA
20
Schonfeld Strategic Advisors
New York
– -$1.02K -19,500 Closed
Bank of America
21
Bank of America
North Carolina
– -$16 -400 Closed
UBS Group
22
UBS Group
Switzerland
– -$8 -200 Closed

ESLAW Hedge Fund Activity: Q3 2023 in Review

11 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q3 2023, worth a combined $212K — down 91% from $2.24M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ESLAW and 2 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 0 added.

The largest buyer was Cowen and Company, opening a new position worth an estimated $4.73K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $2.19M sold.

  • 11 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q3 2023, down from 19 in Q2 2023.
  • Funds reported $212K of Estrella Immunopharma Warrant stock for Q3 2023, down 91% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma Warrant positions in Q3 2023 and 10 closed out, a net change of -8 holders.
  • The largest Estrella Immunopharma Warrant buyer in Q3 2023 was Cowen and Company, an estimated $4.73K added.
  • The largest Estrella Immunopharma Warrant seller in Q3 2023 was Boothbay Fund Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q3 2023.